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Abstract
EpCAM is expressed at low levels in a variety of normal human epithelial tissues, but is overexpressed in 70–90% of
carcinomas. From a clinico-pathological point of view, this has both prognostic and therapeutic significance. EpCAM was
first suggested as a therapeutic target for the treatment of epithelial cancers in the 1990s. However, following several
immunotherapy trials, the results have been mixed. It has been suggested that this is due, at least in part, to an unknown
level of EpCAM expression in the tumors being targeted. Thus, selection of patients who would benefit from EpCAM
immunotherapy by determining EpCAM status in the tumor biopsies is currently undergoing vigorous evaluation. However,
current EpCAM antibodies are not robust enough to be able to detect EpCAM expression in all pathological tissues. Here we
report a newly developed EpCAM RNA aptamer, also known as a chemical antibody, which is not only specific but also more
sensitive than current antibodies for the detection of EpCAM in formalin-fixed paraffin-embedded primary breast cancers.
This new aptamer, together with our previously described aptamer, showed no non-specific staining or cross-reactivity with
tissues that do not express EpCAM. They were able to reliably detect target proteins in breast cancer xenograft where an
anti-EpCAM antibody (323/A3) showed limited or no reactivity. Our results demonstrated a more robust detection of EpCAM
using RNA aptamers over antibodies in clinical samples with chromogenic staining. This shows the potential of aptamers in
the future of histopathological diagnosis and as a tool to guide targeted immunotherapy.
Citation: Shigdar S, Qian C, Lv L, Pu C, Li Y, et al. (2013) The Use of Sensitive Chemical Antibodies for Diagnosis: Detection of Low Levels of Epcam in Breast
Cancer. PLoS ONE 8(2): e57613. doi:10.1371/journal.pone.0057613
Editor: Irina V. Lebedeva, Enzo Life Sciences, Inc., United States of America
Received September 19, 2012; Accepted January 24, 2013; Published February 27, 2013
Copyright:  2013 Shigdar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Royal College of Pathologists of Australasia, National Health & Medical Research Council, Australia (NH &
MRC); Australia-India Strategic Research Fund and Victorian Cancer Agency. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: wduan@deakin.edu.au (WD); lifen_w@163.com (LW)
Introduction
Surgical pathology has become the ‘gold standard’ for the
diagnosis of tumors [1]. When morphological features of the
tumor are not adequate for a definitive diagnosis, immunohisto-
chemistry (IHC) may be of benefit [2]. Indeed, antibodies have
become an integral part of the pathology laboratory in the last 40
years [3]. Biomarkers are identified through the use of antibodies
and molecular techniques, and help to identify particular
characteristics of each tumor including those related to prognosis
[4]. In addition to being an integral part of the diagnostic arsenal,
IHC is also now being used to identify or differentiate those
patients who are likely to benefit from certain directed or targeted
therapies [5,6]. Such is the case in HER2 positive breast cancer
patients who benefit from treatment with trastuzumab [7].
EpCAM is a type I glycosylated membrane protein expressed at
low levels in a variety of human epithelial tissues, but over-
expressed in most solid cancers [8]. Indeed, its expression has been
shown to be inversely related to the prognosis of cancer patients
[8]. The detection of EpCAM on the surface of cancer cells is
becoming increasingly important with the advent of anti-EpCAM
immunotherapy. However, studies have shown that there is
heterogeneity in the reactivity of antibodies against EpCAM,
which could be due to different conformational states when the
epitopes are differentially glycosylated [9,10]. Antibody pro-
duction is a time-consuming process that still relies heavily on
the use of animals for their production, and while monoclonal
antibodies are generally more pure than polyclonal antibodies,
they may be contaminated by antibodies other than the one of
interest when the ascites fluid is collected from the host animal
[11]. An additional problem is that there may be batch-to-batch
variation, with antibodies from different batches directed against
the same epitope showing discrepancies in their staining [11].
Therefore, an alternative to antibodies that does not rely on in vivo
production, and thus eliminates these variables would be highly
advantageous. The generation of chemical antibodies, also known
as aptamers, as an alternative to conventional antibodies is an area
of research that shows promise in expanding the diagnostic and
clinical arsenal in cancer diagnosis and treatment.
We recently reported the generation of a first aptamer against
EpCAM that showed high sensitivity and specificity without any
cross-reactivity [12]. Here we describe the capability of this
aptamer, as well as a second aptamer against EpCAM, as an
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alternative to current EpCAM antibodies for chromogenic
staining of formalin-fixed paraffin-embedded tumor tissues. Our
results demonstrated that our aptamer was more sensitive than the
EpCAM antibody in more than 90% of cases tested. These results
have important clinical significance for breast cancer diagnosis and
developing targeted therapies.
Methods
Ethics Statement
All animal procedures were approved by Deakin University
Animal Welfare Committee and in accordance with the Australian
Code of Practice for the Care and Use of Animals for Scientific
Purposes.
EpCAM Aptamers, Antibodies and Tissue Sections
Aptamers directed against EpCAM were generated as pre-
viously described [12]. Aptamers were chemically synthesized with
29-fluoropyrimidine or 2-O-methyl-pyrimidine bases and a 59-
DY647 or TYE665 or FITC fluorescent tag and a 39-inverted
deoxthymidine (Dharmacon, Victoria, Australia): DT3:59-DY647-
GCGACUGGUUACCCGGUCG-dT- 39; Ep23:59-TYE665–
ACGUAUCCCUUUUCGCGUA-dT-39 or 59-FITC–AC-
GUAUCCCUUUUCGC GUA-dT-39; Control Aptamer: 59-
DY647-mGCmGACUmGmGUUmACCCmGmGUcmG-dT-39.
The monoclonal mouse anti-human EpCAM antibody (323/A3)
was purchased from Abcam (Cambridge, MA). The secondary
antibodies (goat anti-mouse- Alexa FluorH 647, goat anti-
fluorescein-horse radish peroxidase (HRP), or goat anti-mouse-
HRP) were purchased from Life Technologies (Victoria, Austra-
lia), Abcam and Thermo Fisher Scientific (Victoria, Australia),
respectively, while the 3,39-diaminobenzidine (DAB) peroxidase
substrate solution for chromogenic staining was purchased from
Dako (K3467, Victoria, Australia). All antibodies and aptamers
were optimized on positive and negative control tissues prior to the
commencement of the study.
The formalin fixed paraffin embedded (FFPE) sections were
generated from human breast cancer cell lines (T47D, MCF-7,
MDA-MB-231), colon cancer cell line (HT-29) and glioblastoma
cell line (U118-MG) implanted in BALB/c-Foxn1nu mice for
xenograft. HT-29 and U118-MG xenograft sections were used as
positive and negative controls, respectively, throughout all staining
procedures. The FFPE 4 mm tissue sections from breast cancer
patient specimens were randomly selected from archived cases at
Second Affiliated Hospital of Dalian Medical University, Dalian,
China. These samples included eight cases of breast cancer
(invasive ductal carcinoma (n= 7) and mucinous carcinoma
(n = 1)) with matched lymph node metastases (Table 1). Negative
controls were taken from normal liver tissue and xenografts
derived from cell lines that do not express EpCAM were also used.
Patients providing a tumor sample gave written informed consent
to allow release of their archival tumor samples for research
purposes. This study was also approved by institutional Human
Research Ethics Committees.
Quantitation of EpCAM Expression
EpCAM expression in the cell lines used in this study were
analysed qualitatively by flow cytometry and quantitatively by
Western analysis. The EpCAM-FITC antibody (Becton Dick-
erson, Victoria) was used for flow cytometric analysis of EpCAM
expression. Furthermore, the binding sensitivity of the DT3 and
Ep23 aptamers was confirmed against the T47D, MCF-7, MDA-
MB-231 and HT-29 cell lines. Aptamers and antibody were
incubated with the cells at 100 nM or 1:10 dilution for 30 min at
37uC, washed three times and quantified using the flow cytometer.
The expression of EpCAM protein in HT-29, T47D, MCF-7,
MDA-MB-231 and U118-MG cells was analysed by Western
analysis as previously described [13]. Fifteen microlitres of each
sample was loaded onto a 12% NuPAGE Bis-Tris mini gel
(Invitrogen) along with a Precision Plus dual colour protein
standard (BioRad). Following electrophoresis for 45 min at 200 V,
the protein was transferred to a nitrocellulose membrane
(Invitrogen) and blocked with 5% skimmed milk for 3 h at
25uC, before being incubated with either anti-b-actin (Sigma)
diluted 1:2000, or the anti-EpCAM antibody, 323/A3 (Abcam)
diluted 1:250 in 1% skimmed milk, overnight at 4uC. Chemilu-
minescence was detected using an ImageQuantTM LAS 4000
Biomolecular Imager (GE Healthcare).
Immunofluorescent Staining of Animal Xenograft Tissues
Paraffin embedded sections were deparaffinised with Histoclear
and rehydrated through graded ethanols. Heat induced antigen
retrieval was performed in a microwave oven using Tris-EDTA
buffer (10 mM Tris, 1 mM EDTA, 0.05% Tween 20, pH 9.0) for
20 min and the slides were allowed to cool prior to blocking with
0.1 mg/mL tRNA, and 1 mg/mL bovine serum albumin (BSA) or
10% goat serum in phosphate buffered saline (PBS) for 1 h.
Following the blocking step, slides were washed in PBS containing
0.1% Tween 20TM twice for 2 min prior to incubation with either
EpCAM aptamer or antibody. Aptamers (100 nM) were prepared
as previously described [12] and slides were incubated with
aptamers in a solution of PBS containing 5 mM MgCl2, 0.1 mg/
mL tRNA, 1 mg/mL BSA, 10% dextran sulphate and 500 mg/
mL heparin for 15 min at 37uC. The slides were washed in PBS
containing 0.1% Tween 20TM three times for 5 min each prior to
incubation with Bisbenzimide Hoechst 33342 (Sigma, New South
Wales, Australia) (3 mg/mL) for 10 min. Slides were then mounted
using VECTASHIELDH (Vector Laboratories, Burlingame, CA)
and coverslipped.
For EpCAM antibody staining, tissue section preparation,
antigen retrieval and blocking of non-specific binding sites were
carried out under the same conditions as described above. The
sections were probed with the EpCAM antibody 323/A3
(AB8601, Abcam, 1:50 dilution) overnight at 4uC. After two
washes with PBS-Tween-20TM, the tissue sections were incubated
with goat anti-mouse AlexaFluor 647 antibody (A21240, Life
Technologies, 1:200 dilution) for 2 h at room temperature then
counterstained and coverslipped as described for the aptamers.
Negative control slides were performed by replacing the primary
antibody with PBS. Visualization was performed using a Fluoview
FV10i laser scanning confocal microscope (Olympus). All images
used for direct comparison were taken with identical exposure
parameters and are presented without any digital contrast
alteration or background subtraction.
Chromogenic Staining of Human Breast Cancer and
Normal Control Tissues
Normal breast, liver and breast cancer tissues were prepared as
described above. Following antigen retrieval, endogenous perox-
idase was blocked using 0.3% hydrogen peroxide for 20 minutes.
Additional blocking with 10% goat serum and 0.1 mg/mL tRNA
was carried out before aptamer (labeled with fluorescein) or
antibody staining as previously described. A goat anti-mouse anti-
fluorescein HRP secondary antibody (AB6656, Abcam, 1:100
dilution) or a goat anti-mouse HRP secondary antibody (31430,
Thermo Fisher Scientific, 1:500 dilution) was used to develop the
signal from the aptamer or 323/A3 antibody for 2 h, respectively.
The slides were then treated with DAB peroxidase substrate
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solution (Dako) for color development at room temperature for
10 min and counterstained with haematoxylin solution for 5 min
following routine laboratory protocol. Stained sections were
examined under a light microscope equipped with an Olympus
SC20 camera (Victoria, Australia). As a negative control, aptamers
were omitted from the staining reaction. All staining experiments
also included positive and negative control slides (HT-29 and
U118-MG cell line xenografts, respectively). Antigen expression
was defined as specific when a staining signal was present on the
tumor cell membrane. EpCAM expression was evaluated and
compared to the staining intensity of the control cell line (HT-29).
Antigen staining was distinguished as ‘2’ for no staining; ‘1+’ for
faint incomplete staining; ‘2+’ for moderate complete membrane
staining; or ‘3+’ for strong complete membrane staining.
Results
Specific Staining of Cancer Cells in Cancer Xenografts by
EpCAM Aptamers
Protocol optimization was performed using breast and colon
cancer xenograft tissues and fluorescently labeled aptamers or the
EpCAM antibody 323/A3. When incubated in the presence of
dextran sulphate and heparin, the anti-EpCAM aptamers DT3
and Ep23 showed highly sensitive staining for T47D, MCF7 and
MDA-MB-231 human breast cancer xenografts at a concentration
of 100 nM for 15 min at 37uC (Figure 1). Indeed, the staining
pattern correlates well with the reported level of EpCAM
expression on the surface of breast cancer cells [14], as
demonstrated by weaker staining of the MDA-MB-231 xenograft
sections that express much lower amounts of EpCAM than T47D
and MCF7, and as confirmed by flow cytometric analysis and
Western analysis (Figure S1). Also, staining was shown to be highly
specific, with no staining identified for the U118MG xenograft
(EpCAM-negative), or the control aptamer on any of the xenograft
sections (Figure 1).
Aptamers are More Sensitive at Detecting EpCAM than
Antibodies in Cancer Xenografts
As shown in Figure 1 and Table 2, the intensity of antibody
staining for the three different breast cancer xenografts using an
anti-EpCAM antibody 323/A3 was much weaker than that of the
aptamers, in particular aptamer Ep23. However, the antibody
323/A3 did show moderate to strong staining of the HT-29
colorectal cancer xenograft. These results indicate our aptamers
are much more sensitive than one of the standard anti-EpCAM
antibodies in use in pathology laboratories [10,15,16,17]. Among
all the human cancer cell lines studied here, MDA-MB-231 cells
express the lowest amounts of EpCAM (1.76103 binding sites/cell
in MDA-MB-231 vs 222.16103 binding sites/cell in MCF7 [14].
Interestingly, both of our aptamers were able to successfully detect
EpCAM in FFPE sections of a xenograft tumor of MDA-MB-231,
while the EpCAM antibody showed negligible staining (Figure 1),
demonstrating the higher sensitivity of our aptamers.
Robust Detection of EpCAM in Clinical Samples
Since one of our aptamers demonstrated superior staining using
a fluorescence detection system, a chromogenic staining protocol
using this aptamer-substrate system suitable for light microscopy
evaluation was optimized. Archived FFPE histopathology samples
from eight breast cancer patients with matched tumor and lymph
node metastasis sections were independently evaluated for
aptamer and antibody staining intensity. In 14 of the 16 sections,
the aptamer staining intensity of tumor cells was superior to that
seen with the antibody (Table 3, Figure 2). Indeed, in a number of
breast tumors, no obvious staining was observed with the EpCAM
antibody (Figure 2I, J), while the aptamer showed a moderate
positive signal (Figure 2K, L). One lymph node could not be
assessed as only 1% of the lymph node showed tumor and this area
was missing from the section for evaluation. This case was used as
a negative control (Figure 2Y, Z) showing that both the antibody
and aptamer stained specific EpCAM positive cells, and were not
prone to non-specific staining. Interestingly, only one breast ductal
carcinoma showed a slightly superior staining with the antibody
compared to the aptamer (Figure 2Q, R). The specificity of our
EpCAM aptamer was demonstrated by no cross-reactive staining
of the normal cells or lymphocytes within the tissue sections
(Figure 2Z, AA). To confirm that non-specific binding was not the
cause of the increased sensitivity seen with our aptamer, normal
human liver (EpCAM negative) sections were also evaluated for
staining and all showed no discernible DAB signals (Figure 2AB).
Staining of both positive and negative control slides showed
appropriate reactivity indicating the correct optimization of both
antibody and aptamer staining protocols (Figure S2).
Discussion
A sensitive and reliable method for evaluating the expression of
cancer biomarkers in tissue sections is essential for personalized
medicine. EpCAM is a cancer biomarker with its overexpression
documented in both primary and metastatic breast cancers [18].
Increasing EpCAM expression is associated with adverse clinical
Table 1. Clinical Details of Breast Tumor Cases.
Patient
Size of the
tumor (cm)
Pathological
diagnosis
Numbers of
nodes involved
Clinico-pathologic
stage T N M
1 8 invasive ductal carcinoma 1 3a 3 1 0
2 4 invasive ductal carcinoma 8 3a 2 2 0
3 5 invasive ductal carcinoma 7 3c 4 3 0
4 6.5 mucinous carcinoma 2 3a 3 1 0
5 2 invasive ductal carcinoma 23 3c 1 3 0
6 10 invasive ductal carcinoma 43 3c 3 3 0
7 3 invasive ductal carcinoma 0 4 3 0 1
8 1 invasive ductal carcinoma 17 3c 1 3 0
Note: ‘T’: Tumor; N: Node; M: Metastasis.
doi:10.1371/journal.pone.0057613.t001
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outcomes in these patients, especially in metastases [19,20,21]. While it has been suggested that the level of EpCAM expression be
tested in cancer patients [19,22], there is no consensus on the
method to be used [19]. A sensitive and reliable method for
evaluating EpCAM expression is essential for successful immuno-
therapy [22].
Aptamers are small single-stranded DNA or RNA molecules
that are also known as chemical antibodies. This is because of their
ability to fold into complex three-dimensional shapes and bind to
their target in a similar manner to conventional antibodies
[23,24,25,26,27]. One key benefit of these ligands over antibodies
is that they are chemically synthesized, thus reducing many of the
disadvantages of antibodies. Aptamers are produced via a process
known as the systematic evolution of ligands by exponential
enrichment (SELEX), which through iterative rounds, produces
a molecule highly specific for its target [23,24]. An additional
benefit of aptamers is that they can be modified or functionalized
without loss of affinity [28,29]. However, while aptamers show
great promise, there have been limited reports of their use as
probes for IHC [30,31], with only one report to date of the use of
Figure 1. Detection of EpCAM in paraffin embedded tissue using aptamers and antibodies. Immunofluorescence staining of breast
cancer (T47D, MCF7 and MDA-MB-231), colon cancer (HT-29) and glioblastoma (U118MG) xenograft tumors by EpCAM antibody, 323/A3, and EpCAM
aptamers, DT3 and Ep23, and control aptamer (Blue: nuclei; Red: EpCAM positive staining). Aptamer staining was performed for 15 min at 37uC, while
323/A3 staining was performed at 4uC overnight. All fluorescent images were taken under a confocal microscope with660 magnification. Images are
representative of at least three separate experiments. Scale bar: 50 mm.
doi:10.1371/journal.pone.0057613.g001
Table 2. Quantification of anti-EpCAM staining in cell line
xenografts using DT3, Ep23 and control aptamers and 323/A3
antibody by immunofluorescence.
Cell Lines
T47D MCF7 MDA-MB-231 HT-29 U118MG
323/A3 Antibody 1+ 1+ 2 2+/3+ 2
DT3 Aptamer 2+ 1+ 1+ 2 2
Ep23 Aptamer 3+ 2+ 1+ 3+ 2
Control Aptamer 2 2 2 2 2
‘2’ no staining; ‘+’ faint incomplete staining (negative); ‘++’ moderate complete
membrane staining (equivocal); ‘+++’ strong complete membrane staining
(positive) [45].
doi:10.1371/journal.pone.0057613.t002
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aptamers for histopathological diagnosis in paraffin embedded
tissues [30]. However, aptamers can be generated to any protein
target and substituted for antibodies in virtually any application
[32,33,34]. It has been suggested that one of the difficulties
associated with substituting aptamers for antibodies in histopath-
ological protocols is the potential for non-specific staining due to
electrostatic attraction of these polyanion nucleic acid aptamers to
positively charged sites, such as histones, in nucleis [31]. This
could explain the paucity of published data on the use of these
chemical antibodies for histological diagnosis.
Here we demonstrate that aptamers are also suitable for
histological diagnosis. While extensive optimization was required
in the attempt to use these ligands as chemical antibodies, the
realization that these probes are nucleic acids and therefore might
require a combinational approach of both conventional antibody
staining, and methods similar to those used for in situ hybridiza-
tion, led to successful results [35,36,37]. The use of dextran
sulphate has been shown to accelerate the rate of nucleic acid
hybridization [35] thus reducing the time required for aptamer
incubation, while heparin has been shown to reduce background
binding in hybridization procedures [37]. When either of these
two reagents was omitted from the hybridization buffer, positive
staining was not achieved, even when incubation time was
increased. Indeed, this approach was successful for all the
aptamers used for EpCAM staining. We anticipate that this
improved protocol will prove to be highly effective for staining
other biomarkers in FFPE tissues using aptamers and we are
currently investigating this hypothesis.
The sharp contrast between the ability of our EpCAM aptamers
to detect low levels of EpCAM antigen in paraffin embedded
tissues and the lack of staining by conventional antibodies of the
same tumors could be attributed to a number of factors: 1)
Aptamers are 10–20 times smaller (6 kDa vs 150 kDa) than
antibodies and it is therefore possible that higher numbers of
aptamers can bind to a given target molecule compared to
antibodies; 2) It has been well documented that antigen density is
a critical factor in the effectiveness of the detection of antigens by
monoclonal antibodies [38]. Therefore, it is possible that low levels
of EpCAM expression may be missed during diagnosis using
conventional antibody staining. This phenomenon was reported
for the estrogen receptor in an external quality control scheme
(UK-NEQAS-ICC), where tumors expressing low levels of
estrogen receptors were often falsely reported as negative [39].
The staining intensity and sensitivity of our aptamer would
improve detection in these cases. EpCAM staining with our
aptamer showed superior results when compared to the antibody
in both human xenograft tumors via fluorescently labeled aptamer
and in primary human breast cancers using chromogenic staining.
These results are consistent with findings by others that aptamers
display a high level of sensitivity and low background staining
[12,30]. A recent paper has shown that 80% of invasive ductal
breast carcinomas are EpCAM positive [19]. Given the results
from the present study, it is possible that the level of EpCAM
positivity is underestimated in primary and metastatic tumors
using conventional antibodies. It has been suggested that EpCAM
expression in triple-negative breast cancer may be a potential
target for immunotherapy, given its resistance to current targeted
therapies, such as endocrine treatment and trastuzumab [40].
Therefore, accurate and quantitative assessment of the level of
EpCAM expression can better inform the clinician when deciding
on targeted treatment options.
To confirm the sensitivity of our aptamers, we initially chose
several breast cancer cell lines that have a known level of EpCAM
expression on their cell surface, as well as a colon cancer cell line
that has a known high level of EpCAM expression. It has been
reported that HT-29 has 2.3 million EpCAM binding sites on the
Figure 2. Tissue immunostaining of breast cancer and lymph node metastasis by EpCAM antibody and aptamer. A – H: EpCAM
antibody immunostaining was weaker in both the breast tumor (A (640), B (6400) and lymph node (E (640), F (6400) in comparison to EpCAM
aptamer immunostaining in patient 1 (Breast tumor C (640), D (6400); and lymph node G (640), H (6400); I – P No immunostaining was observed
with the EpCAM antibody in the breast tumor (I (640), J (6400) or the lymph node (M (640), N (6400)) while the EpCAM aptamer showed a strong
positive signal in both the breast (K (640), L (6400)) and lymph node (O (640), P (6400)) in patient 5; Q – X Immunostaining with EpCAM antibody
was stronger in the breast tumor (Q (640), R (6400)) but not the lymph node (U (640), V (6400)) than the EpCAM aptamer (Breast tumor S (640), T
(6400); and lymph node W (640), X (6400)) in patient 7; Y – AB Representative images of negative control tissues. Patient 4 showed negative areas
of lymphocyte staining within the lymph node by EpCAM antibody (Y (6400)) and EpCAM aptamer (Z (6400)); Patient 2 showed normal regions of
lymph node that was negative by EpCAM aptamer (AA (6400)); Normal liver sample negative for EpCAM by EpCAM aptamer (AB (6400)). All pictures
were taken under a light microscope with6 40 magnification and6 400 magnification (taken from the center of the6 40 magnification).
doi:10.1371/journal.pone.0057613.g002
Table 3. Immunostaining Comparison of EpCAM Antibody and Aptamer.
Breast Tumor Lymph Node
Case Number Antibody Staining Aptamer Staining Antibody Staining Aptamer Staining
1 2+ 3+ 1+/2+ 2+
2 0 2+ 0 1+/2+
3 0 2+/3+ 1+ 2+
4 0/1+ 2+ No Tumor 1+/2+
5 0 2+/3+ 0 1+/2+
6 0 2+/3+ 1+ 1+/2+
7 3+ 2+ 1+ 1+/2+
8 0 2+ 0 1+/2+
‘2’ no staining; ‘+’ faint incomplete staining (negative); ‘++’ moderate complete membrane staining (equivocal); ‘+++’ strong complete membrane staining (positive)
[45].
doi:10.1371/journal.pone.0057613.t003
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cell surface [41], while T47D and MCF-7 have similar levels of
expression (0.22 million binding sites per cell) [14,42]. These
results were confirmed by Western analysis (Figure S1 I & J).
MDA-MB-231 has a very low level of EpCAM expression, with
a reported 1.7 thousand EpCAM binding sites per cell [14]. The
EpCAM antibody used in this study had an insufficient sensitivity
level to detect EpCAM in the MDA-MB-231 xenograft model.
However, when fully optimized, our aptamer staining protocol was
able to stain this weakly positive EpCAM expressing xenograft
tissue as well as HT-29 xenograft tissue with a dynamic range of 3
orders of magnitude, thus confirming the high sensitivity of our
detection system in paraffin-embedded tissues.
While both aptamers showed a higher sensitivity with the breast
cancer xenografts, aptamer DT3 did not show any positive
staining of the HT-29 xenograft tissues. The binding affinity of
DT3 for HT-29 is 158 nM [12], while Ep23 shows a 4-fold higher
binding affinity for HT-29 (37 nM). This difference in binding
affinities is most probably the cause of the lack of any noticeable
staining due to weaker intermolecular bonds between the aptamer
and the protein. This discrepancy in staining is not a phenomenon
solely associated with aptamers and is observed with antibodies as
well. In the case of EpCAM detection, the Ber-EP4 antibody has
been shown to display false negative results in paraffin embedded
cell blocks [43]. Therefore, as with antibodies, a negative result
needs to be confirmed with additional aptamers to confirm the
lack of expression, rather than the lack of a reaction [44].
Having confirmed the sensitivity of our aptamers on a range of
human cancer cell lines expressing variable levels of EpCAM, we
sought to determine the specificity of our aptamers. Initially, this
was confirmed using a glioblastoma xenograft that does not
express EpCAM [12]. In all cases there was no detectable signal
from either of the aptamers. Once the chromogenic staining
protocol was optimized, several controls testing specificity were
used. Traditional negative controls, such as our glioblastoma
xenograft and normal human liver, were incorporated into each
staining experiment. An additional negative control, the omission
of the aptamer from the staining reaction, was performed for all
tumor cases to confirm the enhanced sensitivity of our aptamer
was not due to non-specific binding of the chromogen. As well,
staining of normal cells was assessed in all lymph node cases.
Specificity was confirmed by the lack of staining of lymphocytes
within each assessed sections with positive staining. The inclusion
of positive and negative control cancer cell line xenografts
provided additional evidence on the specificity of both the
aptamer and antibody. The reliability and reproducibility was
demonstrated by the consistent staining patterns observed with the
positive and negative xenograft tissue sections throughout the
entire study.
Antibodies have previously been considered to be sensitive for
antigen detection. However, here we have shown that when both
the staining conditions for antibodies and aptamers are fully
optimized, aptamers could be more sensitive than conventional
antibodies for the detection of EpCAM. As well, the incubation
times were dramatically reduced (overnight for 323/A3 antibody
vs 15 min for Ep23 aptamer), showing optimal staining with
a shorter reaction time. Additional studies are required to validate
this aptamer as a histological tool for the diagnosis of EpCAM
expression. However, the results from this study demonstrate that
aptamers are not only capable of functioning as chemical
antibodies, but are also more sensitive than conventional
antibodies, at least in the case of EpCAM. As aptamers can be
chemically synthesized and modified easily, they suffer no batch-
to-batch variation, and as they are much more stable than protein
antibodies, this study paves the way for the application of these
molecular probes in future histopathological diagnosis and
potentially for therapeutic applications. Aptamers can provide
a robust and cost-effective tool to translate discoveries from
biomarker and cancer stem cell research into pathology diagnostic
practice to better stratify patients for personalized medicine.
Supporting Information
Figure S1 Determination of EpCAM expression by flow
cytometric analysis and Western analysis. Flow cytometry
was used to confirm EpCAM expression by EpCAM-FITC
antibody and DT3 and Ep23 aptamers. A: Flow cytometry
analysis of EpCAM expression of T47D with DT3 and Ep23
aptamers; B Flow cytometry analysis of EpCAM expression of
T47D with EpCAM-FITC antibody; C: Flow cytometry analysis
of EpCAM expression of MCF-7 with DT3 and Ep23 aptamers;
D: Flow cytometry analysis of EpCAM expression of MCF-7 with
EpCAM-FITC antibody; E: Flow cytometry analysis of EpCAM
expression of MDA-MB-231 with DT3 and Ep23 aptamers; F
Flow cytometry analysis of EpCAM expression of MDA-MB-231
with EpCAM-FITC antibody; G: Flow cytometry analysis of
EpCAM expression of HT-29 with DT3 and Ep23 aptamers; H
Flow cytometry analysis of EpCAM expression of HT-29 with
EpCAM-FITC antibody. Black: negative control; Blue: DT3
aptamer (A, C, E, G); Red: Ep23 aptamer (A, C, E, G); Purple:
EpCAM antibody (B, D, F, H). I: EpCAM expression was
confirmed by Western analysis using the 323/A3 antibody; J:
Relative expression of EpCAM was compared to b-actin.
(TIF)
Figure S2 Representative images of positive and nega-
tive control slides for chromogenic staining. HT-29 and
U118MG tissue sections were stained with either EpCAM
antibody or Ep23 aptamer as part of each staining experiment
of clinical breast cancer cases to confirm specificity of each staining
reaction.
(TIF)
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